Author:
Xu Fan,Huang Min,Bai Yun,Yin Xueshi,Yan Jingzhe,Liu Fangfang,Chen Jie,Weng Xiechuan
Abstract
AbstractPancreatic cancer is a rare but fatal disease. Patients present advanced disease due to the lack of or typical symptoms when the tumor is still localized. A high-quality image processing system has been in practice to detect the pancreatic tumor and determine the possibility of surgery, and preoperative methods, such as ERCP are increasingly used to complement the staging modality. Pancreaticoduodenectomy is one of the complicated surgeries with potential morbidity. The minimally invasive pancreatic resections, both robot-assisted and laparoscopic, have become a part of standard surgical practice worldwide over the last decade. Moreover, advancements in adjuvant chemotherapy have improved the long-term outcomes in current clinical practice. The systemic conservative treatment, including targeted agents, remains the mainstay of treatment for patients with advanced disease. An increasing number of studies are focused on modulating the pancreatic tumor microenvironment to improve the efficacy of the immunotherapeutic strategies. Herein, the role of preoperative therapy, the novel surgical strategy, and individualized systemic treatment in pancreatic cancer is investigated. Also, the randomized controlled studies that have defined the neoadjuvant and surgical management of pancreatic cancer have been summarized.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference43 articles.
1. Sung H, Siegel FJ, Laversanne RL, Soerjomataram M, Jemal I, Bray AF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Arnold M, Neale AC, Vignat RE, Giovannucci J, McGlynn EL, Bray KAF. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335–49.
3. Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.
4. Cerullo M, Gani F, Chen SY, Canner JK, Herman JM, Laheru D, Pawlik TM. Assessing the financial burden associated with treatment options for resectable pancreatic cancer. Ann Surg. 2018;267(3):544–51.
5. Jiao L, Schairer SD, Thiébaut C, Hollenbeck AC, Leitzmann AR, Schatzkin MF, Stolzenberg-Solomon A. Alcohol use and risk of pancreatic cancer: the NIH-AARP diet and health study. Am J Epidemiol. 2009;1(9):1053–51.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献